Immunotherapy for pancreatic cancer

doi:10.12998/wjcc.v9.i13.2969

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6979)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

469

WORD

139

HTML

4364

Figures (1-2)

331

Tables (1-2)

289

Sum=5592

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

440

Download

947

Sum=1387

May 6, 2021 (publication date) through Aug 28, 2024

Times Cited of This Article

Times Cited (22)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Cases. May 6, 2021; 9(13): 2969-2982
Published online May 6, 2021. doi: 10.12998/wjcc.v9.i13.2969

Full Size Figure Download Figure

Figure 2 Illustrations of chimeric antigen receptor T cells immunotherapy. CEA: Carcinoembryonic antigen; ROR1: Receptor tyrosine kinase-like orphan receptor 1; EpCAM: Epithelial cell adhesion molecule; HER2: Human epidermal growth factor receptor 2; MUC1: Mucin 1; CAR: Chimeric antigen receptor.

Citation: Yoon JH, Jung YJ, Moon SH. Immunotherapy for pancreatic cancer. World J Clin Cases 2021; 9(13): 2969-2982
URL: https://www.wjgnet.com/2307-8960/full/v9/i13/2969.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i13.2969